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SUMMARY

To fulfill bioenergetic demands of activation, T cells
perform aerobic glycolysis, a process common to
highly proliferative cells in which glucose is fermented into lactate rather than oxidized in mitochondria. However, the signaling events that initiate aerobic glycolysis in T cells remain unclear. We show T cell
activation rapidly induces glycolysis independent
of transcription, translation, CD28, and Akt and not
involving increased glucose uptake or activity of
glycolytic enzymes. Rather, TCR signaling promotes
activation of pyruvate dehydrogenase kinase 1
(PDHK1), inhibiting mitochondrial import of pyruvate
and facilitating breakdown into lactate. Inhibition of
PDHK1 reveals this switch is required acutely for
cytokine synthesis but dispensable for cytotoxicity.
Functionally, cytokine synthesis is modulated via
lactate dehydrogenase, which represses cytokine
mRNA translation when aerobic glycolysis is disengaged. Our data provide mechanistic insight to
metabolic contribution to effector T cell function
and suggest that T cell function may be finely tuned
through modulation of glycolytic activity.
INTRODUCTION
The activation of T cells to proliferate and develop into armed,
effector cells is a highly regulated process that relies on the balance of multiple signals. T cell receptor (TCR) ligation triggers
tyrosine kinase signaling, and costimulatory signals like CD28
can amplify these signals and engage important serine and threonine kinase cascades such as Akt and mTOR, leading to full
T cell activation and proliferation (Powell and Delgoffe, 2010).
Metabolic and nutrient sensing pathways also play a crucial

role in T cell fate (Pearce et al., 2013). Effector phase T cells
perform aerobic glycolysis, a metabolic state also adopted by
rapidly dividing cells like cancer cells, in which despite the presence of oxygen, glucose is fermented into lactate rather than
oxidized in the mitochondria (Kim and Dang, 2006). Glycolysis
rapidly keeps up with ATP demands in glucose-rich conditions
(Pfeiffer et al., 2001), regenerates NAD+, and preserves the
biosynthetic nature of the mitochondria to generate material to
support proliferation (Delgoffe and Powell, 2015). However, aerobic glycolysis likely not only supports cellular function energetically but also interfaces with the acquisition of effector function
through differentiation (Peng et al., 2016) and support of cytokine
synthesis (Chang et al., 2013).
The molecular mechanism of the initiation of aerobic glycolysis
in T cells and other cell types has been elusive (Palmer et al.,
2015). Most of the glycolytic machinery is present in cells
at baseline, although some proteins have isoforms that promote fermentative or oxidative pathways (pyruvate kinase M1
versus M2 and lactate dehydrogenase a versus b), suggesting
that some transcriptional or post-transcriptional control might
promote aerobic glycolysis (Palmer et al., 2015). Akt-mTOR
signaling can also promote glycolysis through various mechanisms. Akt can phosphorylate GLUT1, facilitating its trafficking
to the cell surface (Jacobs et al., 2008; Wieman et al., 2007);
modify glycolytic enzymes like hexokinase; and transcriptionally
regulate metabolism through modulation of transcription factors
(Eijkelenboom and Burgering, 2013). mTOR can promote glycolysis through activation of hypoxia-inducible factor 1a (HIF1a), as
well as Myc (Pollizzi and Powell, 2014). Yet it remains unclear
whether initiation or commitment to glycolytic metabolism is
an early, post-translationally regulated event or a late, transcriptionally programmed process.
Thus, we sought to dissect signaling events that initiate aerobic glycolysis in T cells and understand whether the kinetics of its
initiation might provide insight into molecular determinants for
these events. We also wanted to determine which T cell effector
functions may be under the influence of rapid glycolysis induced
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Figure 1. T Cells Rapidly Engage Aerobic
Glycolysis upon Activation
(A) Extracellular. acidification rate (ECAR, x axis) and
oxygen consumption rate (OCR, y axis) of PA-R T cells
(plate-bound aCD3 + CD28 activation and expansion
in IL-2) left resting (No Stimulation, NS) or stimulated
for 6 hr with 3 mg/mL aCD3 and 2 mg/mL aCD28.
(B) As in (A), but sorted naive (CD44lo) T cells.
(C) ECAR trace of naive CD8+ T cells equilibrated in
the Seahorse instrument and stimulated via injection
of streptavidin or streptavidin-crosslinked aCD3 at
3 mg/mL and soluble aCD28 at 2 mg/mL.
(D) As in (C), but the OCR trace.
(E) ECAR trace (left) and tabulated data (right) of
PA-R CD8+ T cells stimulated with streptavidin (NS),
streptavidin-crosslinked aCD3, or 1 mM oligomycin
(which stimulates glycolytic reserve)
(F) ECAR trace (left) and tabulated data (right) of
naive CD8+ T cells stimulated as in (E).
(G) Tabulated L-lactate measurements from PA-R
CD8+ T cells stimulated for 1 hr with streptavidin or
streptavidin-crosslinked aCD3 at 3 mg/mL.
(H) As in (G), but with naive CD8+ T cells.
Data are representative of 3 independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001. ns,
not significant by unpaired t test. Error bars represent SEM.

by T cell activation and how the glycolytic machinery might
directly interact with these pathways. We found that TCR activation initiates a signaling event that allows T cells to immediately
perform aerobic glycolysis. This rapid activation-induced glycolysis is directly linked to T cell effector function, allowing T cells to
initiate effector responses shortly after activation.
RESULTS
T Cell Activation Rapidly Induces Aerobic Glycolysis
To determine the glycolytic capacity of T cells in real time, we
employed extracellular flux analysis using a Seahorse XFe96
bioanalyzer. Using both naive and previously activated, rested
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(PA-R) CD4+ and CD8+ T cells, T cells
were activated for 6 hr in vitro with platebound anti-CD3 and anti-CD28, and
oxidative metabolism (oxygen consumption rate [OCR]) and glycolysis (extracellular acidification rate [ECAR]) were
measured. Consistent with previous findings, PA-R and naive T cells switch metabolic states within 6 hr of activation (Figures
1A and 1B) (van der Windt et al., 2013).
To identify when during this 6-hr period
glycolysis may be activated, naive CD8+
T cells were equilibrated in the Seahorse
instrument for 30 min, and streptavidincomplexed anti-CD3 and anti-CD28 were
injected to crosslink the TCR and ligate
CD28. T cells engaged glycolysis within
minutes of TCR activation, reaching a
peak within 15 min and remaining glycolytic for the duration of
the assay (Figure 1C). A concomitant loss of oxidative phosphorylation slowly occurred, reaching equilibrium around 2 hr poststimulation (Figure 1D). Oligomycin treatment, inhibiting mitochondrial ATP synthase and stimulating cells to perform maximal
levels of glycolysis, revealed that TCR ligation immediately and
effectively engaged the entire glycolytic reserve of both PA-R
and naive T cells (Figures 1E and 1F). ECAR activity correlated
to increases in extracellular lactate concentration at time points
consistent with this early change (Figures 1G and 1H). Thus,
T cell activation induces a major metabolic change in the cell,
the stimulation of nearly all capable aerobic glycolysis, within
minutes.

Figure 2. Initiation of Glycolysis in T Cells Is
CD28 Independent
(A) ECAR trace of PA-R CD8+ T cells stimulated
with streptavidin (No Stimulation, NS) or streptavidin-crosslinked aCD3 at 3 mg/mL in the presence
or absence of 2 mg/mL aCD28 (left), and tabulated
results (right).
(B) Tabulated ECAR of PA-R CD8+ T cells stimulated with indicated amounts of streptavidincrosslinked aCD3 in the presence or absence of
aCD28 (left), and trace ECAR (right).
(C) Tabulated ECAR levels of PA-R and naive
CD8+ T cells stimulated for the indicated times with
aCD3 in the presence or absence of 2 mg/mL aCD28
and then assayed in the Seahorse instrument.
Results represent the mean of three (C) or four
(A and B) independent experiments. ***p < 0.001.
ns, not significant by unpaired t test. Error bars
represent SEM.

dispensable for the initiation of glycolysis
that occurs just after TCR engagement.

TCR Signaling Alone Can Mediate Rapid
Activation-Induced Glycolysis
CD28 signaling can sustain glycolysis partly through the
activation of phosphatidylinositol 3-kinase (PI3K)-Akt signaling
(Frauwirth et al., 2002; Jacobs et al., 2008; Zheng et al., 2009).
However, CD28 signaling was dispensable for the rapid initiation
of aerobic glycolysis in both freshly isolated and PA-R CD8+
T cells (Figure 2A; Figure S1A). TCR signal strength determined
the magnitude of glycolytic switching that occurred (Figure 2B;
Figure S1B). Although CD28 has been shown to act as a signal
amplifier for TCR-mediated signals, neither PA-R nor naive
T cells showed enhancement of rapid activation-induced glycolysis when CD28 was combined with suboptimal TCR stimulation
(Figure 2B; Figure S1B), potentially because CD8+ effector
T cells are often considered costimulation independent (Flynn
€llbacher, 1996). Stimulating naive T cells in hours-long
and Mu
culture revealed that although the initial switch to glycolysis
was independent of CD28 signaling (Figures 2A and 2B), sustained glycolytic function required CD28 signaling (Figure 2C),
Thus, although CD28 signaling may be required for initiating transcriptional or translational changes in cellular metabolism, it is

Rapid Activation-Induced
Glycolysis Is Mediated by PDHK1 in
a Manner Independent of
Transcription, Translation, and
Glucose Flux
To examine the nature of this TCRinduced glycolysis, T cells were treated
with actinomycin D or cycloheximide
before activation, showing that neither
new transcription nor translation was
necessary to initiate rapid glycolysis (Figure 3A). Furthermore, fluorescent 2-NBDglucose uptake analysis showed glucose
uptake was not elevated during these
activation time points, occurring only late after stimulation
(24 hr) (Figure 3B). Given that many enzymes in the glycolytic
pathway can be post-translationally modified, TCR-induced
changes in glycolytic enzyme phosphorylation upon T cell activation were measured, showing no changes in phosphorylation
of previously reported modified enzymes in the glycolytic
pathway, including hexokinase, phosphoglycerasemutase,
enolase, pyruvate kinase, or lactate dehydrogenase (LDH) (Figures S2A and S2B). This does not rule out other methods of modulation of glycolytic enzyme activity, but because TCR activation
is driven by phosphorylation, its contribution is likely through this
mechanism. These results suggested that the extracellular acidification observed immediately after T cell activation was not due
to changes in glucose uptake or increases in glycolytic flux but
rather due to changes in glucose processing.
Pyruvate flux into mitochondria is controlled by pyruvate dehydrogenase (PDH), which both facilitates pyruvate import into the
mitochondria and catalyzes its conversion to acetyl-coenzyme A
(CoA) for the tricarboxylic acid (TCA) cycle (Patel et al., 2014).
A prominent form of PDH regulation is modification by phosphorylation by the glycolytic gatekeeper pyruvate dehydrogenase
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Figure 3. TCR-Induced Aerobic Glycolysis Occurs via PDHK1
(A) Tabulated ECAR of PA-R and naive CD8+ T cells stimulated with streptavidin or streptavidin-crosslinked aCD3 at 3 mg/mL in the presence or absence of
transcription or translation inhibition (1 mM actinomycin D [ActD] or 10 mg/mL cycloheximide [CHX]).
(B) Representative histogram of glucose uptake, using PA-R CD8+ T cells reactivated with 3 mg/mL plate-bound aCD3 + 2 mg/mL soluble aCD28 for the indicated
times and then pulsed with 2NBDG.
(C) Representative immunoblot (IB) of indicated phospho- or total proteins in lysates from PA-R CD8+ T cells stimulated for the indicated periods with streptavidin
or streptavidin-crosslinked aCD3 at 3 mg/mL in the presence of 2 mg/mL aCD28 (left), and tabulated densitometry scanning (right).
(D) ECAR trace of PA-R CD8+ T cells stimulated with streptavidin (No Stimulation, NS) or streptavidin-crosslinked aCD3 at 3 mg/mL and 2 mg/mL aCD28 in the
presence or absence of the indicated amounts of dichloroacetate (DCA) (left), and tabulated ECAR (right).
(E) Tabulated L-lactate measurements from PA-R CD8+ T cells stimulated with streptavidin (NS) or streptavidin-crosslinked aCD3 at 3 mg/mL in the presence of
absence of 20 mM DCA.
(F) ECAR trace of PA-R CD8+ T cells stimulated as in (D) and then injected with 20 mM DCA (left), and tabulated ECAR (right).
(G) Immunoblot of PDHK1, its enzymatic target pS PDH, and ZAP-70 (as a loading control) from CD8+ T cells retrovirally expressing scrambled control shRNA
(shCTRL) or shRNA to Pdk1 (encoding PDHK1) (left), and tabulated densitometry scanning (right).
(H) ECAR trace of cells from (G) stimulated with crosslinked aCD3 at 3 mg/mL, followed by 20 mM DCA, 10 mM 2-deoxy-d-glucose (2DG), and 500 nM rotenone/
antimycin A (left), and tabulated ECAR (right).
Results represent three (A–C, E, and G), four (F and H), or five (D) independent experiments. *p < 0.05, **p < 0.01, ****p < 0.0001 by unpaired t test. ns, not
significant. Error bars represent SEM.

kinase 1 (PDHK1, encoded by Pdk1) (Patel et al., 2014), resulting
in inhibition of PDH function, blocking pyruvate flow into mitochondria, and facilitating lactic acid conversion by LDH. In can-
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cer, PDHK1 can be phosphorylated by oncogenic tyrosine kinases, stimulating its function to promote glycolysis (Hitosugi
et al., 2011). Tyrosine phosphorylation of PDHK1 (measured

Figure 4. Proximal TCR Signaling Molecules Interact with PDHK1
(A) Immunoblot of immunoprecipitations of the indicated proteins in lysates from CD8+ T cells stimulated with streptavidin or streptavidin-crosslinked aCD3 at
3 mg/mL and aCD28 at 2 mg/mL for the indicated times.
(B) Immunoblot of immunoprecipitations of PDHK1 from HEK293T cells transfected with the indicated combinations of Lck, LAT, ZAP-70, and PDHK1 expression
vectors.
(C) TIRF microscopy images of OT-I T cells stimulated on aTCR and ICAM-1 containing stimulatory lipid bilayers for 15 min and then stained intracellularly for total
and phospho-PDHK1 (left), and Pearson’s correlation in proximity to TCR (right).
(D) Immunoblot of indicated proteins in lysates from PA-R CD8+ T cells stimulated with streptavidin (No Stimulation, NS) or streptavidin-crosslinked aCD3 at
3 mg/mL in the presence or absence of the indicated inhibitors (left), and tabulated densitometry (right).
(E) Tabulated ECAR of PA-R CD8+ T cells stimulated as in (D) in the presence or absence of the indicated inhibitors (left), and trace ECAR of Lck inhibition (right).

(legend continued on next page)
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using a phosphotyrosine immunoprecipitation and immunoblotting, and a specific phosphotyrosine antibody in whole-cell
lysates) was rapidly induced upon TCR ligation and in a CD28independent manner in T cells (Figure 3C; Figure S2C). We
employed dichloroacetate (DCA), a specific inhibitor of PDHK1,
to block activity of PDHK1 in the presence of TCR signals (Jha
and Suk, 2013; Kankotia and Stacpoole, 2014; Michelakis
et al., 2008). Inhibition of PDHK1 with DCA prevented the initiation of glycolysis in PA-R T cells, shown both using Seahorse
ECAR and direct lactate measurements (Figures 3D and 3E).
The activity of PDHK1, read out by its phosphorylation of PDH,
was also increased upon T cell activation and inhibited by DCA
treatment (Figure S2D). Furthermore, DCA treatment of T cells
already undergoing rapid activation-induced glycolysis reduced
ECAR to preactivation levels (Figure 3F).
To support the hypothesis that activation-induced PDHK1
activity alters the path of glucose processing, freshly isolated
T cells were stimulated with anti-CD3 alone in normal glucose
containing media for 30 min and then pulsed with uniformly
labeled 13C-glucose for another 30 min to conduct isotopic flux
analysis (Figure S2E). Glucose-derived pyruvate levels were
unchanged at 30 min between resting and stimulated cells,
confirming prior notions that glycolytic enzymatic activity that
produces pyruvate from glucose was not altered by TCR activation (Figure S2F). 13C-labeled lactate was markedly increased
in the media in response to TCR signaling in a DCA-dependent
manner (and thus PDHK1-dependent manner) (Figure S2G).
Finally, consistent with the notion that PDHK1 activation inhibits
pyruvate processing in the mitochondria, less incorporation of
labeled carbon was observed in the TCA cycle intermediates
malate and citrate in response to stimulation, which was mitigated by DCA treatment (Figures S2H and S2I). However, only
glucose-derived TCA cycle activity was inhibited, because the
abundance of unlabeled TCA cycle intermediates remained
unchanged regardless of treatment (Figure S2J).
Genetic targeting of PDHK1 was also employed to determine
its role in glycolytic switching. PDHK1 was knocked down using
retroviral RNA interference during CD8+ T cell expansion (Figure 3G), revealing a significant decrease in activation-induced
glycolysis (Figure 3H). Thus, PDHK1 is an important signaling
node induced by early T cell activation that facilitates the rapid
switch in the bioenergetic fate of glucose.
The Glycolytic Gatekeeper PDHK1 Is Activated by Early
TCR Signaling
TCR engagement induces tyrosine phosphorylation of several
kinases, and previous studies have suggested that, in cancer,
oncogenic receptor tyrosine kinases (RTKs) bind to and phosphorylate PDHK1, especially FGFR1 (Hitosugi et al., 2011).
Two TCR-induced kinases, ZAP-70 and Lck share significant
homology with FGFR1, suggesting these might bind to PDHK1.
PDHK1 was coimmunoprecipitated with Lck at steady state,

and upon activation, PDHK1 bound ZAP-70 suggesting these
proteins might exist in a complex (Figure 4A). ZAP-70-deficient
Jurkat T cells failed to engage rapid glycolysis upon stimulation
with OKT3 (Figures S3A and S3B). To determine to which early
TCR signaling molecules PDHK1 directly interacted with upon
T cell activation, HEK293T cells were transfected with different
combinations of PDHK1, linker of activated T cells (LAT), and
constitutively active Lck or Zap70 to study their interactions in
a non-T cell system (Levin et al., 2008). PDHK1 could bind
directly to Lck or Lat, but interaction with Zap70 required the
presence of Lck or Lat (Figure 4B). Total internal reflection fluorescence (TIRF) microscopy of PA-R T cells on stimulatory lipid
bilayers revealed that that total and phosphorylated PDHK1
were present at and were significantly associated with the
T cell synapse upon T cell activation (Figure 4C).
To determine whether more distal signaling pathways were
engaging the glycolytic machinery, T cells were treated with
the minimal effective doses of several reported signaling module
inhibitors induced during TCR activation, confirming Lck inhibition prevented PDHK1 phosphorylation and rapid activationinduced glycolysis (Figures 4D and 4E) and preventing the interaction of PDHK1 and Zap70 (Figure 4F). In stark contrast, Akt,
mTOR, ERK, PI3K, PLC, protein kinase C (PKC), and calcium
flux were dispensable for induction of rapid glycolysis and phosphorylation of PDHK1 (Figures 4D and 4E; Figure S3C). These
results were particularly surprising because Akt has been implicated in early-immediate glycolysis in human memory T cells
(Gubser et al., 2013). PI3K-Akt was also not sufficient to induce
glycolysis, because in-Seahorse stimulation of PI3K with a PTEN
inhibitor did not engage glycolysis (Figure S3D). Likewise, T cells
from Rictorf/fCd4Cre mice, in which Akt cannot be phosphorylated by mTORC2 (Pollizzi et al., 2015), were still able to initiate
glycolysis after activation (Figure S3E).
Another previously reported contributor to glycolysis is HIF1a,
which promotes glycolysis through transcriptional and posttranslational changes, including the upregulation of PDHK1
(Lee and Simon, 2012). Naive T cells from Hif1af/fCd4Cre mice
were able to initiate rapid glycolysis, as well as their wild-type
counterparts (Figure S3F). Activation and expansion of HIF1adeficient T cells revealed their basal glycolysis was lower than
that of wild-type cells, consistent with the notion that HIF1a
promotes a transcriptional glycolytic program (Figure S3G).
However, these previously activated HIF1a-deficient T cells
induce rapid glycolysis upon reactivation to the same degree
relative to their basal levels, indicating that PDHK1’s role in
glycolysis is distinct from that of HIF1a (Figures S3G and S3H).
Hyperactivation of PKC alone using the phorbol ester phorbol
12-myristate 13-acetate (PMA) can also initiate glycolysis in
PA-R T cells, but to a lesser degree, with distinct kinetics and
without engaging PDHK1 (Figures S3I and S3J). Thus, the initiation of glycolysis occurs directly downstream of the TCR in an
Lck-dependent manner via the kinase PDHK1.

(F) Immunoblot of immunoprecipitations of the indicated proteins in lysates from PA-R CD8+ T cells stimulated as in (A) for the indicated times in the presence or
absence of 10 nM Lck inhibitor.
Results represent the mean of three (A, D, and F), four (B), five (E), or seven (C) independent experiments. *p < 0.05 by unpaired t test. ns, not significant. Error bars
represent SEM.
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Rapid Activation-Induced Glycolysis Regulates Distinct
Acute Effector Functions
Aerobic glycolysis has been previously shown to be critical
for T cell effector function, as measured by cytokine production, but used interchangeably with oxidative phosphorylation
(OXPHOS) to meet the metabolic needs of T cell proliferation
and expansion (Chang et al., 2013; Palmer et al., 2015). Consistent with these reports, at high doses, DCA-mediated PDHK1
inhibition had effects on proliferation after 96 hr (Figure S4A).
Because this pathway is induced minutes after activation, its major importance may be to support the early-immediate, rapid
effector function of T cells competent to produce cytokines.
Previous reports have suggested glycolysis is important for the
synthesis of cytokine in typical stimulation conditions (Chang et al.,
2013). Inhibition of PDHK1 in the early phase inhibited the ability
of effector CD8+ T cells to rapidly synthesize interferon gamma
(IFNg), interleukin (IL)-2, or tumor necrosis factor alpha (TNFa)
early after TCR activation (1 hr–6 hr) (Figures 5A and B). DCA treatment also inhibited cytokine production in overnight activation,
suggesting that although this switch is induced quickly upon activation, it is used later into the activation phase to facilitate cytokine
synthesis and secretion (Figure 5C). To fully interrogate effector
function, the cytotoxic potential of T cells was also examined.
Inhibition of PDHK1-mediated glycolysis had a minimal effect on
cytolytic capacity (Figure 5D), and DCA-treated cells were still
able to produce the cytolytic molecules perforin and granzyme B
(Figure S4B). PDHK1 inhibition by DCA was not toxic to the cells
(Figure S4C). Consistent with the role of PDHK1 as a gatekeeper
enzyme rather than a promoter of glycolytic flux, PDHK1 inhibition
did not change the ability of T cells to take up glucose (Figure S4D).
PDHK1 inhibition had similar effects on in vivo-generated CD8+
effector T cells, using OT-I transfer and ovalbumin (OVA)-expressing Vaccinia virus: inhibition of cytokine production (Figure S4E)
and preserved cytotoxic function in vivo (Figure 5E).
Although we and others have shown that aerobic glycolysis
promotes acute effector function of T cells, there have been reports that aerobic glycolysis also promotes IFNg competency
during Th1 differentiation through a long-term, epigenetic mechanism (Peng et al., 2016). These studies were done with LDHdeficient animals, which have essentially irreversible inhibition
of aerobic glycolysis. Employing pharmacological and reversible
inhibition of aerobic glycolysis via DCA could thus both confirm
the role of aerobic glycolysis in T cell differentiation and reveal
a role for this pathway in acute effector function of T cells. Similar
to previous reports using LDH-deficient T cells, inhibiting glycolysis for 7 days using the PDHK1 inhibitor DCA during PA-R
T cell generation prevented T cell differentiation, as evidenced
by an inability to produce IFNg (Figure S4F). In addition, genetic
targeting using retroviral RNA interference caused a decrease in
cytokine production but had no effect on perforin or granzyme B
production or the ability for the cells to kill their targets in vitro
(Figures S4G–S4I). However, this inhibited cytokine synthesis
occurred even when PDHK1 was active during the restimulation
(DCA treatment during differentiation but washed out before restimulation) (Figure S4F). This suggests that aerobic glycolysis
plays a secondary, long-term role in maintaining the T cell differentiation state in a manner distinct from the control of acute cytokine production we and others have observed.

Our previous data suggested that naive T cells also engaged
this rapid glycolytic switch in response to TCR stimulation (Figures 1 and 2). Because naive T cells generally are not cytokine
competent, we explored the contribution of this early glycolytic switch to their function, taking advantage of the reversibility
of DCA-mediated PDHK1 inhibition. Washout experiments, in
which DCA was only present during 12 hr of initial stimulation,
revealed that this early glycolytic switch was dispensable for
expansion of naive T cells, suggesting that its contribution might
be limited to the acute phase (Figure S5A). In addition, when
PDHK1 was inhibited only during activation, it did not negatively
affect glucose uptake, mitochondrial mass or polarization, or
the ability for T cells to produce IFNg after restimulation, suggesting that PDHK1-mediated glycolysis is especially important
for short-term functions in response to acute activation (Figures
S5B and S5C). Although naive T cells do not synthesize cytokine,
they rapidly make other chemical mediators, including chemokines like CCL3. Naive (CD62LhiCD44lo) OT-I T cells stimulated
with peptide and antigen presenting cells (APCs) for 5 hr revealed CCL3 production was strikingly dependent on glycolysis
(Figure S5D). Thus, it appears that this rapid metabolic change
is important, both in naive and in PA-R effector T cells, in early,
acute synthetic functions of T cells.
Rapid Activation-Induced Glycolysis Supports
Post-transcriptional Control of Cytokine Synthesis
through LDH
Although, as demonstrated earlier, aerobic glycolysis can
contribute to effector function by promoting epigenetic changes
supporting T cell differentiation, our data and others’ also suggest a more immediate role for glycolysis in acute effector function. Although T cells undergo this major metabolic change during their early cytokine-producing phase, they do not increase
their ability to take up glucose (Figure 3B). This suggested that
the ability to engage aerobic glycolysis and thus support effector
function would depend on the availability of glucose in the environment, acting as a sensor for nutrient availability. To test this,
PA-R T cells were stimulated for a short time (3 hr) in the Seahorse in various suboptimal concentrations of glucose, revealing
that the extent of PDHK1-mediated aerobic glycolysis depended
on the availability of glucose, reaching saturation around 5 mM,
after which no more glucose could be fermented (Figure 6A).
Measurement of IFNg secretion from these same Seahorse
assay wells by ELISA revealed that cytokine production, while
occurring in even zero-glucose conditions, showed a substantial
increase as glucose availability increased (Figure 6B). This is in
agreement with previous data suggesting cytokine synthesis
was linked to extracellular glucose availability (Blagih et al.,
2015). DCA treatment during the assay revealed that this supplemental cytokine synthesis depended on the PDHK1-mediated
switch (Figure 6B). However, neither glucose concentrations
nor PDHK1 activity appreciably changed the mRNA levels of
Ifng (or Tnf or Il2) cytokine transcripts, even though these cells
produce lower amounts of these proteins in either short-term
(3 hr) or long-term (overnight) stimulations (Figures 6B and 6C;
Figure S6). Studies have revealed a role for metabolic enzymes,
especially GAPDH, in modulating cytokine mRNA stability
(Chang et al., 2013). However, GAPDH, an enzyme several steps
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Figure 5. PDHK1-Mediated Glycolysis Is Required for Cytokine Production but Dispensable for Cytotoxic T Cell Function
(A) Tabulated IFNg ELISA data from PA-R CD8+ T cells, in which cells were pretreated with 20 mM DCA 30 min before 1-hr activation via streptavidin-crosslinked
aCD3 at 3 mg/mL.
(B) Representative flow cytogram (left) and tabulated cytokine production (right) from PA-R CD8+ T cells stimulated for 6 hr with 3 mg/mL aCD3 and 2 mg/mL
aCD28 in the presence or absence of 20 mM DCA.
(C) Representative flow cytogram (left) and tabulated cytokine production (right) from PA-R CD8+ T cells stimulated overnight with 3 mg/mL aCD3 and 2 mg/mL
aCD28 in the presence or absence of 5 mM DCA.
(D) Quantified in vitro cytotoxicity assay using PA-R OT-I T cells cultured with OVA-expressing or parental B16 melanoma cells in the presence or absence of
5 mM DCA.
(E) Representative cytogram (left) and tabulated results (right) of an in vivo cytotoxicity assay in which OT-I cytotoxic T lymphocyte (CTL) were generated in vivo
with vaccinia virus (VV)OVA, after which mice receive an adoptive transfer of control or cognate-peptide-loaded splenocyte targets differentially labeled with CFSE
and an immunoprecipitation (IP) injection of either PBS or DCA.
Results represent the mean of five (C), four (B), or three (A, D, and E) independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001 by unpaired t test. Error bars
represent SEM.

upstream of pyruvate, is used for glucose processing regardless
of whether pyruvate is oxidized in mitochondria or fermented
into lactate, and DCA treatment fails to inhibit GAPDH activity
(Schmidt et al., 2011). However, LDH, which catalyzes the interconversion of pyruvate and lactate and is the only glycolytic
enzyme with differential function in DCA-treated cells, has also
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been shown to have RNA-binding function. Previously studies
have shown that it, like GAPDH, binds the AU-rich element
(ARE) present in the 30 UTR of mRNAs like granulocyte-macrophage colony stimulating factor (GM-CSF) and with greater affinity than GAPDH (Pioli et al., 2002). We activated PA-R CD8+
T cells overnight in the presence or absence of DCA and

Figure 6. PDHK1-Mediated Aerobic Glycolysis Integrates Glucose Availability and LDH Activity to Control Cytokine Synthesis at the Posttranscriptional Level
(A) Tabulated ECAR generated from PA-R CD8+ T cells stimulated with streptavidin or streptavidin-crosslinked aCD3 at 3 mg/mL in the presence or absence of
20 mM DCA in the indicated concentration of glucose.
(B) IFNg production from supernatant collected from the flux analysis experiment in (A) measured by ELISA.
(C) qPCR analysis of cDNA generated from RNA extracted from PA-R CD8+ T cells stimulated overnight with 3 mg/mL aCD3 and 2 mg/mL aCD28 in the presence
or absence of DCA. mRNA levels of the indicated cytokines were standardized with Actb expression.
(D) qPCR analysis of cDNA generated from RNA IP using LDHA-specific antibodies or a species-specific control. Precipitates were prepared from PA-R CD8+
T cells left resting or stimulated with 3 mg/mL aCD3 and 2 mg/mL aCD28 in the presence or absence of DCA overnight and then crosslinked with 1% formaldehyde
before RNA IP. Results are expressed as fold enrichment over species-specific control (IgG).
(E) IFNg and IL-2 production (measured by flow cytometry) of WT CD8+ T cells stimulated with 3 mg/mL aCD3 and 2 mg/mL aCD28 in the presence of DCA.
(F) IFNg and IL-2 production of T cells stimulated with 3 mg/mL aCD3 and 2 mg/mL aCD28 from mice homozygous for a targeted deletion of the Ifng AU-rich
element (ARE) (DA) or littermate controls.
Results represent the mean of three (A–D) or two (E and F) (n = 5–7 mice per group) independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001 by two-way
ANOVA (A) unpaired t test (B–F). Error bars represent SEM.

performed RNA immunoprecipitation using anti-LDH antibodies
(Figure 6D). LDH bound mRNA transcripts for the cytokines
IFNg, TNFa, and IL-2 in resting T cells, but upon activation,
this binding was significantly reduced. Inhibition of PDHK1mediated glycolysis during activation resulted in enhanced binding of LDH to cytokine mRNA, suggesting that LDH may be mediating post-transcriptional regulation of these cytokine transcripts

(Figure 6D). LDH failed to bind transcripts for the cytotoxicity
gene Gzmb, which lacks an ARE in its 30 UTR (Figure 6D), supporting the notion that cytolytic capacity does not require glycolysis (Figure 5E; Figures S4B, S4H, and S4I). These experiments
were conducted using a full overnight stimulation to induce
optimal transcription and translation of cytokine rather than using an acute activation protocol. However, the PDHK1-mediated

Cell Reports 22, 1509–1521, February 6, 2018 1517

glycolytic switch is important for optimal elaboration of cytokine
even in overnight stimulatory conditions (Figure 5C). To confirm
the role of the ARE in LDH-mediated mRNA control, T cells were
assayed from mice in which the Ifng 30 UTR has been replaced
with a scrambled nucleotide insertion, resulting in transcript
that is the same size as wild-type Ifng but lacks the ARE (Hodge
et al., 2014). T cells with this mutation are resistant to DCA-mediated inhibition of IFNg synthesis (Figures 6E and 6F). Specificity
of this effect was confirmed, because IL-2 was still repressed
with DCA treatment in IfngDARE T cells (Figure 6F). Thus, the
initiation of aerobic glycolysis in T cells promotes effector cytokine production partly through the alleviation of LDH-mediated
repression of mRNA translation.
DISCUSSION
The immune response interfaces heavily with metabolic and
nutrient sensing pathways, the study of which has garnered interest in recent years (Rathmell, 2012). Although it has been
known for decades that lymphocytes carry out aerobic glycolysis during activation (Roos and Loos, 1973), it has only recently
become clear which signals may initiate or sustain this metabolism. In addition, the functional relevance of aerobic glycolysis, in particular the epigenetic and post-transcriptional control
of effector function, has just been realized (Chang et al., 2013;
Peng et al., 2016; van der Windt et al., 2013). Our results reveal
four previously unappreciated aspects of activation-mediated
metabolic reprogramming.
First, our data suggest that rapid activation-induced glycolysis, occurring immediately after TCR ligation, bears hallmarks
that make this metabolic pathway distinct from the aerobic
glycolysis of actively proliferating T cells. It occurs in a transcription- and translation-independent manner and does not enhance
or require increased glucose uptake in T cells. Rather, our
studies support a model in which this rapid activation-induced
glycolysis is a distinct metabolic switch promoting pyruvate to
lactate conversion immediately after activation to support
short-term effector function.
Second, although CD28 and Akt signaling have previously
been shown to be critical for the upregulation of metabolic machinery and the maintenance of glycolysis throughout expansion
(Frauwirth et al., 2002; Rathmell et al., 2003; Zheng et al., 2009),
the initiating events of glycolysis, occurring almost immediately
after T cell activation, are CD28 and Akt independent. Although
Akt has been associated with rapid induction of glycolysis
previously using effector memory cells (Gubser et al., 2013),
our studies using the minimal inhibitory dose of Akt/PI3K inhibition, as well as genetic deletion of the Akt kinase, reveal this
pathway is dispensable for this rapid-activation-induced glycolysis, at least in murine effector T cells. It is possible that Akt may
be playing a larger role in bona fide memory T cells (rather than
in vitro-generated PA-R T cells) to promote this metabolic
switch, suggesting additional complexity in the regulation of
these signaling pathways in distinct differentiation states.
Third, our studies suggest that PDHK1-mediated initiation of
aerobic glycolysis, while required for optimal cytokine production and secretion (Chang et al., 2013), is dispensable for other
effector functions, such as proliferation and cytolytic function.
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Our studies are in agreement with previously published data
implicating glycolysis in the post-translational control of cytokine
translation (Blagih et al., 2015; Chang et al., 2013) but reveal that
cytotoxicity is an effector function that can be distinguished,
metabolically, from cytokine production. Furthermore, using
PDHK1 inhibition as a reversible inhibitor of LDH activity, we
confirmed that aerobic glycolysis plays a role in regulation of
differentiation in a manner that is distinct from its control of
acute effector function. This was accomplished using DCA,
which pharmacologically but reversibly inhibits PDHK1 activity.
Although we confirmed the metabolic and functional roles of
PDHK1 using RNA interference, the irreversibility of genetic deletion made separating acute functional versus epigenetic or differentiation effects difficult. Future directions will employ inducible genetic inhibition experiments to more specifically inhibit
PDHK1’s activity. PDHK1 activity has been previously reported
in CD4+ T helper cells as selectively important for PMA- and ionomycin-elicited IL-17 cytokine production (Gerriets et al., 2015).
Our data in CD8+ T cells are largely in agreement with this previous work, although by stimulating using TCR crosslinking (antiCD3 and/or cognate peptide), we have revealed that additional
cytokines (Ifng, Il2, and Tnfa) are under control of PDHK1-mediated aerobic glycolysis. In addition, by using in vivo-generated
effector T cells using Vaccinia virus, we highlight the link between
our in vitro-generated findings in vivo biological significance,
although more elegant detection methods will surely enable
future functional and metabolic analysis of acutely activated
T cells in in vivo disease settings.
Fourth, our data support a role for LDH as a key node linking
aerobic glycolysis and cytokine production. LDH, like GAPDH
and other metabolic enzymes, binds AREs present in cytokine
(and presumably chemokine) transcripts, repressing translation
in a non-glycolytic state. Thus, part of the glycolytic phenotype
is the relief of cytokine mRNA from LDH-mediated translational
repression. Because key cytotoxic granule genes like Gzmb
and Prf1 lack an ARE in their 30 UTR, they are not regulated
by aerobic glycolysis, in concordance with our functional data.
Our data in naive T cells show that CCL3, a chemokine rapidly
secreted in response to activation, is also under glycolytic
control: it too bears an ARE in its 30 UTR (Kang et al., 2011),
suggesting that a range of proteins may be modulated in
response to rapid glycolysis. These data provide evidence
that rapid activation-induced glycolysis is a general T cell phenomenon, regardless of differentiation state. It is the goal of
future work to determine the full implication of these findings,
such as other mRNA sequences regulated by glycolytic enzymes and differences in regulated mRNA between T cell types
and differentiation states.
In agreement with previous reports (Chang et al., 2013), inhibition of aerobic glycolysis during short-term activation (30 min to
6 hr) does not repress cytokine production, resulting in a consistent 40%–50% reduction in cytokine levels. We believe is not a
technical issue but rather indicative of real biology. This pathway,
by its nature, does not increase glucose uptake or glycolytic
processing; it changes how pyruvate is metabolized, thereby
affecting the activity of LDH. Thus, our data support a model in
which, during early T cell activation, glycolysis acts as a rheostat
or throttle for cytokine production, tuning the amount of cytokine

translation to match the metabolic state of the microenvironment, which we confirmed in glucose titration experiments.
This has wide-ranging implications for T cell activation in the tissues, which typically possess far lower concentrations of
glucose than typical cell culture media. Of particular interest is
activation in the tumor microenvironment, which has dramatically reduced concentrations of glucose and increased levels
of lactic acid, which both may alter the ability of even optimally
activated T cells to effectively synthesize cytokines (Ho et al.,
2015; Scharping and Delgoffe, 2016). It is the goal of future
work to translate these mechanistic insights, identifying how
glycolytic activity and subsequent effector molecule synthesis
may be modulated during in vivo activation, especially in environments in which nutrients may be limited or abundant.
Many other cell types demonstrate rapid effector functions,
synthesizing cytokines hours after activation, which may be
regulated by this rapid activation-induced glycolysis. In support
of this, we have shown that mast cells stimulated through the
FcεR rapidly trigger glycolysis that is important for their cytokine
production (Phong et al., 2017). We anticipate other rapid cytokine-producing cells will use similar tyrosine signaling cascades
to promote rapid glycolysis, including FcgR-stimulated natural
killer (NK) cells, invariant natural killer T (iNKT) cells, and B cells.
Previous studies have implicated glycolysis in T cell activation,
avoidance of anergy, and the bias of effector versus memory differentiation (Frauwirth et al., 2002; Gubser et al., 2013; Jacobs
et al., 2008; Sukumar et al., 2013; van der Windt et al., 2013;
Zheng et al., 2009). Many studies use 2-deoxy-d-glucose
(2DG), which inhibits the entire glycolytic pathway starting at
hexokinase, as well as N-linked glycosylation (Zhang et al.,
2014). Other studies have use galactose, which through the
Leloir pathway can still enter the glycolytic process (Bustamante
and Pedersen, 1977). In addition, some studies have used
steady-state genetic perturbations many of these enzymes
(Peng et al., 2016). Inhibition of PDHK1, in contrast, does not
perturb glucose flux or enzymatically perturb any stage of glycolysis, which effectively targets only the activation-induced glycolytic pathways (Zhang et al., 2015). Furthermore, we believe that
using pharmacological, reversible inhibition of this switch rather
than genetic deletion has confirmed the role of this pathway in
epigenetic control of differentiation, as well as acute control of
effector function.
Our data support a model placing these early, key changes in
glucose metabolism central to the execution of the acute effector
T cell program in differentiated, cytokine competent cells, as well
as early synthesis programs like chemokine production even in
naive T cells. This is initiated by the TCR at the level of PDHK1
and is functionally modulatory at the level of LDH. This antigen
receptor-mediated, rapid activation-induced glycolysis constitutes a metabolic pathway that is fundamentally distinct from
those longer-term, transcriptionally regulated changes that
characterize proliferating T cells. Our work also suggests that
different functions of lymphocytes may be effectively distinguished through metabolic means. As such, understanding
how these distinct metabolic pathways interface with immune
effector programs may allow for the use of metabolic intervention
to functionally modulate the immune response with greater
precision.

EXPERIMENTAL PROCEDURES
Mice
All animal work was done in accordance with the Institutional Animal Care and
Use Committee of the University of Pittsburgh. All mice were housed in specific
pathogen-free conditions before use. Both male and female mice were used,
and mice were 6–8 weeks old at time of use. C57BL/6, OT-I, Cd4Cre, and
Hif1af/f mice were obtained from The Jackson Laboratory. Mice lacking the
ARE of Ifng were generated by Dr. Howard Young (National Cancer Institute
[NCI]). Rictorf/fCd4cre and littermate controls were obtained from Dr. Jonathan
Powell (Johns Hopkins University).
T Cell Isolations
Spleen and lymph node CD4+ and CD8+ T cells were magnetically isolated
from 6- to 8-week-old mice as previously described (Scharping et al., 2016).
Naive T cells were isolated using CD44 (IM7)-biotin-activated magnetic depletion or by flow cytometric sorting (CD8+ or CD4+ CD62LhiCD44lo) on a Beckman Coulter Mo-Flo Astrios High Speed Cell Sorter.
PA-R T Cell Generation
To generate PA-R T cells, CD4+ or CD8+ T cells were freshly isolated from
C57BL/6 and stimulated at 10 3 106/mL in complete RPMI with plate-bound
anti-CD3 (3 mg/mL, BD Biosciences) and anti-CD28 (2 mg/mL, BD Biosciences), or spleen or node preparations harvested from OT-I mice were stimulated with 250 ng/mL SIINFEKL peptide (AnaSpec) in the presence of 50 U/mL
IL-2 (PeproTech) for 24 hr. Cells were then expanded into complete RPMI supplemented with 50 U/mL IL-2 for 1 day, 25 U/mL IL-2 for an additional 4 days,
and then 10 U/mL IL-2 for an additional 1–2 days. Some were also cultured
with DCA (CAS 2156-56-1) (Fisher). Vaccinia-OVA, generated by J.R. Bennink
(Bacik et al., 1994) and provided by Dr. Jonathan Powell (Johns Hopkins
University), was used as previously described to generate previously activated
cells in vivo (Scharping et al., 2016).
Metabolic Assays
Naive or PA-R T cells were plated on Cell-Tak-coated Seahorse Bioanalyzer
XFe96 culture plates (300,000 or 100,000 cells/well, respectively) in assay media consisting of minimal, unbuffered DMEM supplemented with 1% BSA and
25 mM glucose, 2 mM glutamine, and for some experiments, 1 mM sodium
pyruvate. Basal rates were taken for 30 min, and then streptavidin-complexed
anti-CD3bio at 3 mg/mL ± anti-CD28 at 2 mg/mL or PMA (CAS 16561-29-8)
(Fisher) was injected and readings continued for 1–6 hr. In some experiments,
oligomycin (2 mM), carbonyl cyanide p-trifluoromethoxyphenylhydrazone
(FCCP) (0.5 mM), 2-deoxy-d-glucose (10 mM) rotenone/antimycin A (0.5 mM),
and DCA (20 mM) were injected to obtain maximal respiratory and control
values. Inhibitors used for some experiments include 5–50 mM DCA, 10 nM
Lck inhibitor RK24466 (CAS 213743-31-8), 500 nM Akt inhibitor VIII (CAS
612847-09-3), 500 nM rapamycin (CAS 53123-88-9) (Cayman Chemical),
10 mM ERK inhibitor U0126 (CAS 109511-58-2), 10 mM PI3K inhibitor
LY294002 (CAS 154447-36-6), 100 nM PKC inhibitor sotratorin (CAS
425637-18-9), EDTA (CAS 67526-95-8), actinomycin D (CAS 50-76-0), cycloheximide (CAS 66-81-9) (Cayman Chemical), 500 nM U-73122 PLCɣ inhibitor
(CAS 112648-68-7) (Sigma), and EGTA (CAS 67-42-5) (Fisher). For Jurkat T cell
experiments, wild-type (WT) or ZAP-70-deficient cells were stimulated with
OKT3 (BioLegend) complexed using anti-mouse immunoglobulin G (IgG).
Because ECAR values tend to vary among experiments, most figure panels
have both a representative trace and normalized data (calculated as the
difference between maximal and basal ECAR values). Lactate was measured
using the colorimetric kit from Abcam.
Retroviral RNA Interference
Short hairpin RNA (shRNA) retroviral constructs were purchased from
OriGene, and OT-I T cells were transduced as previously described (Scharping
et al., 2016), except that puromycin (2 mg/mL) was used for selection.
Immunoblotting and Immunoprecipitation Analysis
Immunoblotting was performed as previously described (Delgoffe et al., 2009).
Naive or PA-R T cells were stimulated with anti-CD3bio at 3 mg/mL complexed
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with streptavidin at 1.5 mg/mL (AnaSpec) for various times in the presence or
absence of anti-CD28 at 2 mg/mL or with PMA. HEK293T cells transfected
with combinations of Lck, LAT, ZAP-70, or PDHK1 overexpression vectors
(A. Weiss) were used (no stimulation). All antibodies for IP or immunoblots
(IBs) were obtained from Cell Signaling Technology except pPDH (S293)
from Novus Biologicals and b-actin from Santa Cruz Biotechnology. IBs
were detected via standard secondary detection and chemiluminescent
exposure to film. Digitally captured films were analyzed densitometrically by
ImageJ software.
Microscopy
Immunological synapse formation was analyzed in response to lipid
bilayer stimulation as previously described (Guy et al., 2013). Briefly, lipid
bilayers containing ICAM-1 and Alexa Fluor (AF)647-labeled anti-TCR
antibodies were prepared. Resting OT-I CD8+ T cells were stimulated
for 30 min before fixation with 4% paraformaldehyde, permeabilization
with 0.1% T-100, and staining with antibodies overnight at 4 C. AF568conjugated secondary antibodies and AF488-conjugated phalloidin (Fisher)
were applied for 1 hr before analysis using TIRF microscopy. Images
were acquired using an inverted TiE Nikon microscope equipped with a
1003 1.45 numerical aperture (NA) oil objective, motorized TIRF illumination, Andor DU-897 high-speed electron-multiplying charge-coupled device
(EMCCD) camera, and Agilent laser launch. Analysis of fluorescent intensities for each channel were determined for individual pixels using Nikon
Elements software.
Functional Readouts
Cytokine production and proliferation were assessed as previously described
(Scharping et al., 2016), with some minor changes. CD8+ T cells were stimulated with 1 to 3 mg/mL plate-bound anti-CD3 and 2 mg/mL soluble antiCD28 (for C57BL/6 T cells) or 250 ng/mL SIINFEKL peptide + antigen-presenting cells (for OT-I T cells) for 3–24 hr (final 4 hr in the presence of brefeldin A)
and then stained intracellularly for cytokines, or secreted IFNg was measured
using an ELISA assay. For naive T cell functional assays, CD62LhiCD44lo OT-I
T cells were purified flow cytometrically, stimulated for 5 hr with T cell-depleted
splenocytes and SIINFEKL peptide in the presence of brefeldin A, and then
stained intracellularly for CCL3 (BioLegend). In vitro cytotoxicity was assessed
as previously described (Scharping et al., 2017). In vivo cytotoxicity was
measured as the change in the ratio of carboxyfluorescein succinimidyl ester
(CFSE)hi (OVA peptide loaded) to CFSElo (irrelevant control) cells after adoptive
transfer of OT-I T cells and differentially CFSE-labeled target cells relative to
naive mice.
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